Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: May 7, 2025
Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook
Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase
Read more at globenewswire.comNASDAQ:CPRX (6/13/2025, 10:18:06 AM)
23.37
-0.92 (-3.79%)
Find more stocks in the Stock Screener
CPRX Latest News and Analysis
6 days ago - ChartmillCATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Rare Combination of Growth and ValueCATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and an attractive valuation, making it a standout in biotech.
9 days ago - ChartmillCATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for CANSLIM InvestorsCATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A technical uptrend and reasonable valuation add to its appeal.
11 days ago - ChartmillCATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Growth InvestorsCATALYST PHARMACEUTICALS INC (CPRX) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, revenue growth, and solid financial health. A detailed analysis highlights its potential for investors.
20 days ago - ChartmillCATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Quality InvestorsCatalyst Pharmaceuticals (CPRX) shows strong fundamentals, high profitability, and zero debt, making it a compelling choice for quality investors. The stock trades at reasonable valuations with solid growth prospects.
